ACVRL1 and pulmonary arterial hypertension: Previous pre-clinical studies demonstrated that exogenous administration of recombinant human wild type BMP9 (WT BMP9) enhances BMPR2/ALK1 mediated signaling and reverses experimental pulmonary hypertension in rat models.